CED Life Science Conference 2018 - presenting at the Coulter Investment Forum
Sub-sector: Medical Device
Year Founded: 2016
MicroElastic Ultrasound Systems, founded in 2016, is developing a handheld device that quantifies the elasticity of skin at the touch of a button. Skin elasticity is important for evaluating elective treatments like anti-aging therapies, and crucial for tracking skin manifestations of difficult-to-manage diseases like Graft-Versus-Host-Disease (GVHD). For doctors who need reliable measurements to make decisions about when to treat, what to treat with, and for how long, the standard of care remains a “pinch-and-score” test which in both inherently qualitative and unreliable. Indeed, the NIH working group on GVHD has declared that “There is an urgent need for the development of more quantifiable and reproducible measurements or imaging methods that could be used in patients with sclerotic skin manifestations of chronic GVHD”. MicroElastic has built its proprietary technology, developed at Duke, into a functional prototype for clinical testing, which uses high frequency ultrasound to vibrate and characterize the skin’s elastic properties directly, providing a repeatable and reliable numeric measurement. MicroElastic is currently preparing for FDA 510(k) submission, funded by an NIH STTR grant for the GVHD application, and is also generating interest in the aesthetic industry for its direct application to anti-aging procedures.
Peter Hollender, Ph.D. Founder and CEO
Mark Palmeri, MD, Ph.D. Chief Scientific Advisor
Rich McGivney, CFO
KEY MILESTONES TO DATE
- Three international Patents filed
- Two years Duke-Coulter Translational Research Partnership funding ($300k)
- NIH Phase I STTR (National Cancer Institute) ($150k)
- Clinical trial planned spring 2018
- Strategic partnership in development
Learn more about the CED Life Science Conference.